Alzheimer’s Drug?
Allysia Finley opines in The Wall Street Journal on June 24 that the FDA was correct in its overriding of its Advisory Board’s recommendation to reject the application of Biogen’s drug aducanumab. The agency approved it for treatment of early Alzheimer’s disease. The drug is reputed to reduce amyloid plaque in the brain and reduce cognitive decline. As Ms. Finlay points out, the clinical trials were not perfect in their conclusions but there was some signal of benefit at high drug doses.